BARRIE,
ON, Nov. 9, 2022 /PRNewswire/ -
MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:
MLZ) ("MediPharm" or the "Company") a pharmaceutical
company specialized in precision-based
cannabinoids, is pleased
to announce it will release second
quarter financial results for the three and
nine month period ended September
30, 2022, before markets
open on Monday, November 14, 2022.
MediPharm's executive management team will also host a
conference call and audio webcast on Monday, November
14, 2022, at 8:30 a.m. Toronto time to discuss the Company's
financial results and outlook.
Audio
Conference Call Dial in Details:
Toll-free number: 1 (888) 330-2454 /
International number: 1 (240) 789-2714
/ Conference ID: 4921762
Participants are asked to dial in approximately 15 minutes before the start of the call.
Audio Webcast:
An audio webcast will be available
in the Events section of the MediPharm
website https://www.medipharmlabs.com/investors or by
visiting the following link here.
For those who are unable to participate on the live conference
call or webcast, a replay will be available approximately
one hour after completion of the call.
About
MediPharm Labs Corp.
Founded in 2015, MediPharm specializes in the development and
manufacture of purified, pharmaceutical-quality cannabis
concentrates, API and advanced derivative products utilizing a Good
Manufacturing Practices certified facility with ISO standard-built
clean rooms. MediPharm has invested in an expert, research driven
team, state-of-the-art technology, downstream purification
methodologies and purpose-built facilities with five primary
extraction lines for delivery of pure, trusted and precision-dosed
cannabis products for its customers. Through its wholesale and
white label platforms, MediPharm formulates, develops (including
through sensory testing), processes, packages and distributes
cannabis extracts and advanced cannabinoid-based products to
domestic and international markets.
In 2021, MediPharm received a Drug Establishment Licence from
Health Canada, becoming the only company in North America to hold a domestic Good
Manufacturing Practices licence for the extraction of natural
cannabinoids. The Company carries out its operations in compliance
with all applicable laws in the countries in which it operates.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:
This news release contains "forward-looking information" and
"forward-looking statements" (collectively,
"forward-looking statements") within the meaning of the
applicable Canadian securities legislation. All statements, other
than statements of historical fact, are forward-looking
statements and are based on expectations, estimates and projections
as at the date of this news release. Any statement that
involves discussions with respect to predictions, expectations,
beliefs, plans, projections, objectives, assumptions, future events
or performance (often but not always using phrases such as
"expects", or "does not expect", "is expected", "anticipates" or
"does not anticipate", "plans", "budget", "scheduled", "forecasts",
"estimates", "believes" or "intends" or variations of such words
and phrases or stating that certain actions, events or results
"may" or "could", "would", "might" or "will" be taken to occur or
be achieved) are not statements of historical fact and may be
forward-looking statements. Forward-looking statements are
necessarily based upon a number of estimates and assumptions that,
while
considered reasonable, are subject to known and unknown risks,
uncertainties, and other factors which may cause the actual
results and
future events to differ materially from those expressed or implied by such forward-looking statements. Such factors
include, but are not limited to: general business,
economic, competitive, political and social uncertainties; the
inability of MediPharm to obtain adequate financing; the delay or
failure to receive regulatory approvals; and other factors
discussed in MediPharm's filings, available on the SEDAR website at
www.sedar.com. There can be no assurance that such statements will
prove to be accurate, as actual results and future events
could differ materially from those anticipated in such
statements. Accordingly, readers should not place undue
reliance on the forward-looking statements and information
contained in this news release.
Except as required by law, MediPharm
assumes no obligation to update the forward-looking statements of beliefs, opinions,
projections, or other factors, should they change.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/medipharm-labs-sets-date-to-report-third-quarter-2022-financial-results-301673474.html
SOURCE MediPharm Labs Corp.